2018 Webcasts
Webcasts from HIV Glasgow are being added to the Congress website as and when approvals are received. We will continue to populate this page with more information as it becomes available.
Sunday 28 October
Monday 29 October
Tuesday 30 October
Wednesday 31 October
Sunday 28 October
Interactive Case Study Session
In collaboration with the University of Liverpool Drug Interactions website:
www.hiv-druginteractions.org
HIV pharmacology in 2018 Webcast
Saye Khoo, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
Case 1: TB co-infection Webcast
Marta Boffito, HIV and Sexual Health – Kobler Clinic, Chelsea Westminster Hospital, London, UK
Case 2: HIV-HCV and PWIDS
Erica Peters, Brownlee Centre for Infectious Diseases, NHS Greater Glasgow Clyde, Glasgow, UK
Case 3: Pregnancy Webcast
Mas Chaponda, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
Discussants: Fiona Marra, Advanced Pharmacist HIV/HCV, Gartnavel Hospital, Glasgow, UK
Mohammed Lamorde, Infectious Diseases Institute, Makerere University,
Kampala, Uganda
Jonathan Schapiro, National Hemophilia Center, Sheba Medical Center,
Tel Aviv, Israel
Official Opening and Welcome from Glasgow City Webcast
Andrew Phillips, University College London, London, UK
and
Bailie Ade Aibinu, Glasgow City Council, Glasgow, UK
Opening Scientific Session
Celebrating a Champion of the Response to HIV Webcast
Remembering David Cooper
Tribute by: Sean Emery, University of New South Wales, Sydney, Australia
Joep Lange and Jacqueline van Tongeren Memorial Lecture: Introduction
Introduction by: Praphan Phanuphak Webcast
Joep Lange and Jacqueline van Tongeren Memorial Lecture: HIV/AIDS, global health and the Sustainable Development Goals Webcast
Kevin M De Cock, CDC Country Office, Nairobi, Kenya
Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS
Strategies to reduce HIV incidence in Europe Webcast
Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
PrEP: what’s happening in Europe and the World in general Webcast
Sheena McCormack, MRC Clinical Trials Unit at UCL, London, UK
Monday 29 October
Living Well with HIV: Ongoing Challenges
Co-Chairs:Peter Reiss, Department of Global Health, Amsterdam UMC, University of
Amsterdam, Amsterdam, The Netherlands
Caroline Sabin, Institute for Global Health, University College London,
London, UK
Retention and re-engagement in care: a combination approach again
required Webcast
Fiona Burns, Centre for Sexual Heath and HIV Research, and Royal Free Hospital, London, UK
HIV and ageing: challenges and goals Webcast
Julian Falutz, Department of Medicine, McGill University, Montreal, Canada
48-week changes in biomarkers in subjects with high cardiovascular risk switching from ritonavir-boosted protease inhibitors to dolutegravir: the NEAT022 study Webcast
Esteban Martinez, Infectious Disease, Hospital Clínic & University of Barcelona, Barcelona, Spain
Risk of hospitalisation according to gender, sexuality and ethnicity among people with HIV in the modern ART era Webcast
Sophia Rein, Institute for Global Health, University College London, London, UK
Multimorbidity and risk of death differs by gender in people living with HIV in the Netherlands: the ATHENA cohort study Webcast
Ferdinand Wit, Stichting HIV Monitoring, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands
The economic burden of comorbidities among people living with HIV in Germany: a cohort analysis using health insurance claims data Webcast
Eva Wolf, MUC Research, Munich, Germany
Discussion Webcast
In Memory of Mark Wainberg Webcast
Mark made an enormous contribution to both the basic science and global politics of the HIV epidemic. He was a president of the International AIDS Society, received Canada’s highest civilian award and was an extremely active member of the scientific committee of HIV Glasgow for over 20 years.
Tribute by: Ian Weller, University College London, London, UK
Lock Lecture
HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme
Lock Lecture: introduction Webcast
David Galloway, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK
STIs among MSM: new challenges in prevention, diagnosis and treatment Webcast
Jean-Michel Molina, Department of Infectious Diseases and University of Paris 7, St Louis Hospital, Paris, France
Comorbidities: Lunchtime Poster Discussion Session
Co-Chairs:Georg Behrens, Department for Clinical Immunology and Rheumatology, Hannover
Medical School, Hannover, Germany
Sarah Pett, UCL Institute of Clinical Trials and Methodology, London, UK
Incidence and risk factors associated with osteoporosis-related fractures (ORF) among PLWHIV in British Columbia (BC), Canada Webcast
José Barletta, Infectious Diseases Division, Hospital Juan A. Fernández, Buenos Aires, Argentina
Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60 Webcast
Franco Maggiolo, USC Malattie Infettive, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo Italy
Haematological manifestations in virologically-suppressed people living with HIV Webcast
Delal Akdag, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
Increases in lipid profile after switch from TDF to TAF-based HAART regimens in a cohort of HIV-positive patients: is it clinically relevant? Webcast
Lidia Gazzola, Infectious Disease, ASST Santi Paolo e Carlo, Milan, Italy
Factors associated with HIV-associated neurocognitive disorder in an unselected cohort in East and South London: the HAND study Webcast
Simon Rackstraw, HIV, Barts Health NHS Trust, London, UK
Substances, Drugs and Outcomes: Lunchtime Poster Discussion Session
Co-Chairs:Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town,
Cape Town, South Africa, and Immediate Past-President, IAS
Simon Collins, HIV i-Base, London, UK
Risky Alcohol Consumption and Associated Health Behaviour among HIV-positive and HIV-negative Patients in a UK Sexual Health and HIV Clinic: the HAZAL Study Webcast
Emmi Suonpera, Institute for Global Health, University College London, London, UK
Chemsex drugs on the rise among MSM: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 Webcast
Benjamin Hampel, Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid (Spain): a population-based study Webcast
Juan Berenguer, Instituto de Investigacion Sanitaria, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies Webcast
Rajith Rajoli, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects Webcast
Terry Farrow, Pharmacovigilance & Epidemiology, Gilead Sciences, Foster City, CA, USA
Drug Interactions, ARV Toxicity and Switching
Co-Chairs:Anastasia Antoniadou, Division of Internal Medicine IV, National and
Kapodistrian, University of Athens, Athens, Greece
David Back, Molecular and Clinical Pharmacology, University of Liverpool, UK
The top 10 DDIs in day to day clinical management of HIV Webcast
Catia Marzolini, Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
Adverse effects of current ARVs: myths and realities
Paddy Mallon, Mater Misericordiae University Hospital, Dublin
Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP (n=15,678) Webcast
Victoria Pilkington, Faculty of Medicine, Imperial College London, London, UK
Dual therapy with PI/r+3TC or PI/r+TDF shows non-inferior HIV RNA suppression and lower rates of discontinuation for adverse events, versus triple therapy. Meta-analysis of seven randomised trials in 1624 patients Webcast Poster
Zara Liew, Faculty of Medicine, Imperial College London, London, UK
No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial Webcast
Babafemi Taiwo, Division of Infectious Diseases, Northwestern University, Chicago, IL, USA
Challenging Cases in HIV Treatment and Prevention
In collaboration with the International Antiviral Society-USA (IAS-USA)
Moderators:Carlos del Rio, Rollins School of Public Health, Atlanta, GA, USA
Ian Williams, Institute for Global Health, University College London,
London, UK
Welcome and introduction Webcast
Carlos del Rio
Case 1: PrEP Webcast
Roy M Gulick, Weill Cornell Medicine, New York, NY, USA and Carlos del Rio
Case 2: ART: initiating treatment Webcast
Chloe Orkin, Ambrose King Centre, Royal London Hospital, London, UK
Case 3: ART: treatment failure? Webcast
Manuel Battegay, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
Closing remarks Webcast
Ian Williams
Tuesday 30 October
Approaches to Treatment and Cure
Co-Chairs:Giulia Marchetti, Dept of Health Sciences, Clinic of Infectious Diseases,
University of Milan, Milan, Italy
Jonathan Schapiro
Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: Week 96 Webcast
Hans-Jürgen Stellbrink, ICH Study Center, Hamburg, Germany
Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in antiretroviral treatment (ART)-naïve, HIV-1-infected adults: AMBER Week 96 results Webcast
Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London, London, UK
Comparable viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy Webcast
Babafemi Taiwo, Division of Infectious Diseases, Northwestern University, Chicago, IL, USA
The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients Webcast
Flaminia Olearo, Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
Approaches towards a cure for HIV Webcast
Sarah Fidler, Department of GUM and HIV Medicine, Imperial College and Imperial College NHS Trust, London UK
HIV cure and cancer immunotherapy: cross-disciplinary research at its best Webcast
Steven G Deeks, Department of Medicine, University of California, San Francisco, CA, USA
Quality of Life Across Different Age Groups of People Living with HIV: A Community Perspective
In collaboration with the European AIDS Treatment Group (EATG)
Co-Chairs:Lene Ryom, Centre of Excellence for Health, Immunity and
Infections, Copenhagen, Denmark
Alain-Volny Anne, Paris, France
Introduction and Project Overview Webcast
Koen Block, EATG, Brussels, Belgium
People living with HIV/AIDS aged 50+ Webcast
Brian West, EATG, Edinburgh, UK
Giovanni Guaraldi, Infectious Diseases, Univesity of Modena and Reggio Emilia, Modena, Italy
Children and adolescents (aged 0-25) Webcast
Sanja Belak Skugor, University Hospital for Infectious Disease, Zagreb, Croatia
Caroline Foster, Imperial College NHS Trust, London, UK
People who have lived with HIV/AIDS at least 10 years (aged 18-50) Webcast
Jackie Morton, EATG, UK
Ferdinand Wit
Panel Discussion Webcast
Georg Behrens, Nikos Dedes, EATG, Athens, Greece, Koen Block, Sanja Belak Skugor
#Adolescent Lives Matter
In collaboration with the International AIDS Society (IAS)
Moderators:Yana Panfilova, Student, Academy of Labour, Social Work and Tourism, Kiev,
Ukraine, and HIV activist and founder of Teenergizer, a youth movement
Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town,
Cape Town, South Africa, and Immediate Past-President, IAS
Living with it: complications of long term HIV Webcast
Rashida Ferrand, London School of Hygiene and Tropical Medicine, London, UK, and Harare, Zimbabwe
Taking it: PrEP experiences among adolescent MSM Webcast
Sybil Hosek, John Stroger Hospital of Cook Country, Chicago, IL, USA
Staying with it: novel ways to increase adolescent adherence Webcast
Caroline Foster
Dealing with it: mental health and stigma: report from a cohort of YPLHIV in the Ukraine Webcast
Heather Bailey, Population, Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK
Adolescent friendly – really? Webcast
Mercy Ngulube, Chair, Children’s HIV Association’s Youth Committee, UK
Panel Discussion Webcast
Mental Health and HIV: what we all need to know
In collaboration with the British HIV Association (BHIVA)
Co-Chair:Tamás Bereczky, European AIDS Treatment Group, Budapest, Hungary
Chloe Orkin, Ambrose King Centre, Royal London Hospital,
London, UK; and Chair, BHIVA
Introduction Webcast
Chloe Orkin
Prevalence of mental health problems among people living with HIV Webcast
Fiona Lampe, Infection & Population Health, University College London, London, UK
BHIVA Mental Health Audit Webcast
Chloe Orkin
Discrimination in EU healthcare: the community perspective Webcast
Yonatan Shimells, AIDES, Paris, France
Important DDIs: to include QT/PR interval concerns Webcast
Laura Waters, Mortimer Market Centre, University College London Hospitals, London, UK
Q & A Webcast
All
Wednesday 31 October
HIV and Migration: a renewed challenge
Co-Chair:Karine Lacombe, Infectious and Tropical Diseases Department, Saint-Antoine
Hospital (AP-HP), Paris, France
Stefan Mauss, Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
HIV and migration: a renewed challenge Webcast
Julia Del Amo, National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain
Co-infections: TB and Viral Hepatitis
HIV-associated tuberculosis: diagnosis, management and prevention Webcast
Graeme Meintjes, University of Cape Town, Cape Town, South Africa
Eliminating hepatitis C: a public health perspective Webcast
Margaret Hellard, Burnet Institute, Melbourne, Australia; and Viral Hepatitis Services, Department of Infectious Diseases, The Alfred Hospital Melbourne, Australia
Minimum prices of generic hepatitis C direct acting antivirals fall below US$50 per person cured Webcast Poster
Andrew Hill, Translational Medicine, University of Liverpool, Liverpool, UK
Long-term follow-up of HIV-HBV co-infected patients according to the use of anti-HBV active drugs Webcast
Andrea Calcagno, Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
What Women Want
Joint session in collaboration with the European AIDS Clinical Society (EACS) and Women Against Viruses in Europe (WAVE)
Co-Chairs:Justyna D Kowalska, Hospital for Infectious Diseases, Medical
University of Warsaw, Warsaw, Poland
Fiona Mulcahy, Department of Genito-Urinary Medicine & Infectious
Diseases, St James’ Hospital, Dublin, Ireland
PrEP for women in Europe: case presentation and lecture Webcast
Agnieszka Wroblewska, HIV Out-Patient CLinic, Hospital for Infectious Diseases, Warsaw, Poland
Nneka Nwokolo, Sexual Health and HIV Medicine, Chelsea and Westminster Hospital, London, UK
Pharmacokinetic studies in women and its impact on clinical practice: case presentation and lecture Webcast
Eugénie Colin-Benoit, Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland
Karoline Aebi-Popp, Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland
HCV treatment and pregnancy: case presentation and lecture Webcast
Marta Vasylyev, Out Patient Department, Lviv Regional AIDS Center, Lviv, Ukraine
Karine Lacombe, Infectious and Tropical Diseases Department, Saint Antoine Hospital (AP-HP), Paris, France
Higher rate of virological failure in women compared to men when starting dual antiretroviral treatment: sex-specific analysis from the Frankfurt HIV Cohort Webcast
Benjamin Koenigs, HIV Center, University Hospital Frankfurt, Frankfurt, Germany
Successes and emerging challenges in prevention of vertical HIV transmission in the UK and Ireland Webcast
Helen Peters, Great Ormond Street Institute of Child Health, University College London, London, UK
HCV co-infection is a strong risk factor for pre-term birth among HIV-positive women on cART – data from HIV Out-Patient Clinic in Warsaw Webcast
Karolina Nowicka, Medical University of Warsaw, Hospital for Infectious Diseases, Warsaw, Poland
ART: Lunchtime Poster Discussion Session
Co-Chairs:Nadia Ahmed, Centre of Excellence for Adolescents Health and
Wellbeing, Desmond Tutu HIV Foundation and Faculty of Health
Sciences, University of Cape Town, Cape Town, South Africa
Ian Williams
High prevalence of previously undocumented baseline M184V/I does not affect virologic outcome in virologically-suppressed patients switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from a boosted-protease inhibitor-based regimen Webcast
Richard Haubrich, Medical Affairs, Gilead Sciences, Foster City, CA, USA
Comparison of viral replication below 50c/mL for two drug (DTG+RPV) versus three drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies Webcast
Mark Underwood, Clinical Virology, ViiV Healthcare, Research Triangle Park, NC, USA
Safety, efficacy and durability of long-acting CAB and RPV as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 Week 160 results Webcast
David Margolis, Clinical Development, ViiV Healthcare, Research Triangle Park, NC, USA
Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naïve adults with HIV-1 infection: subgroup analyses in the GEMINI studies Webcast
Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London, London, UK
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort Webcast
Alessandra Vergori, L.Spallanzani, IRCCS HIV/AIDS Unit, National Institute for Infectious Diseases, Rome, Italy
An HIV outbreak among people who inject drugs in Glasgow
Co-Chairs:Andrew Leigh Brown, University of Edinburgh, Edinburgh, UK
Emma Thomson, Centre for Virus Research, Institute of Infection,
Immunity & Imflammation, Glasgow, UK
Introduction Webcast
Andrew Leigh Brown
Using real-time phylodynamic analysis to assess and guide public health interventions in an HIV outbreak among PWIDs in Scotland Webcast not available
Amanda Bradley-Stewart, Virology, NHS Greater Glasgow and Clyde, Glasgow, UK
Is early ART achievable in PWIDs living with HIV? Webcast
Rebecca Metcalfe, NHS Greater Glasgow and Clyde Brownlee Centre, Gartnavel General Hospital, Glasgow, UK
An outbreak of HIV amongst homeless PWIDs: an innovative HIV clinical service model adaptation leading to successful clinical outcomes
Erica Peters
Providing HIV ARVs via community pharmacies alongside opiate replacement therapy (ORT) during an HIV outbreak amongst PWIDs Webcast
Regina O’Hara, Brownlee Outpatients, Gartnavel General Hospital, Glasgow, UK
Nurses at the forefront: a new HIV service model for PWIDs in Glasgow Webcast
Patricia Anderson, Brownlee Centre, Gartnavel General Hospital, Glasgow, UK
Late Breakers/Hot Topics
Co-Chairs:Deniz Gökengin, Department of Infectious Diseases and Clinical Microbiology
Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey
Roy M Gulick
New ARV drugs and strategies Webcast
Alexandra Calmy, HIV/AIDS Unit, Geneva University Hospitals, Geneva, Switzerland
Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial Webcast
Eric Delaporte, TransVIHMI et CHU Montpellier IRD-INSERM, Université Montpellier, Montpellier, France
Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates Webcast
Jay Grobler, Infectious Disease Biology, Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Week 48 safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants (BRIGHTE Study) Poster
and
Phase 3 Study of fostemsavir in heavily treatment-experienced HIV-1 infected participants: BRIGHTE Week 48 subgroup analysis in randomized cohort
participants Poster
Peter Ackerman, Clinical Development, ViiV Healthcare, Branford, CT USA Webcast
Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program Webcast
Zvi Cohen, Medical Affairs, Theratechnologies Inc., Montreal, Canada
Distribution in cerebrospinal fluid (CSF) of cabotegravir (CAB) and rilpivirine (RPV) after intramuscular administration of long-acting (LA) injectable suspensions in HIV-1 infected patients Webcast Poster
Scott Letendre, Antiviral Center, University of California, San Diego, CA, USA
Congress Closing Remarks Webcast
Giulio Corbelli, EATG, Brussels, Belgium and Bologna, Italy
Andrew Phillips
